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Abstract
‘Autoantigen complementarity’ is a theory proposing that the initiator of an autoimmune response 
is not necessarily the autoantigen or its molecular mimic, but may instead be a peptide that is 
‘antisense/complementary’ to the autoantigen. We investigated whether such complementary 
proteins play a role in the immunopathogenesis of autoimmune glomerulonephritis. Experimental 
autoimmune glomerulonephritis, a model of anti-glomerular basement membrane (GBM) disease, 
can be induced in Wistar Kyoto (WKY) rats by immunization with the α3 chain of type IV 
collagen. In this study, WKY rats were immunized with a complementary α3 peptide (c-α3-Gly) 
comprised of amino acids that ‘complement’ the well characterized epitope on α3(IV)NC1, 
pCol(24–38). Within 8 weeks post-immunization, these animals developed cresentic 
glomerulonephritis, similar to pCol(24–38)-immunized rats, while animals immunized with 
scrambled peptide were normal. Anti-idiotypic antibodies to epitopes from c-α3-Gly-immunized 
animals were shown to be specific for α3 protein, binding in a region containing sense pCol(24–
38) sequence. Interestingly, anticomplementary α3 antibodies were identified in sera from patients 
with anti-GBM disease, suggesting a role for ‘autoantigen complementarity’ in 
immunopathogenesis of the human disease. This work supports the idea that autoimmune 
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glomerulonephritis can be initiated through an immune response against a peptide that is anti-
sense or complementary to the autoantigen. The implications of this discovery may be far 
reaching, and other autoimmune diseases could be due to responses to these once unsuspected 
‘complementary’ antigens.
INTRODUCTION
As early as 1983, an article was published in the Lancet postulating how viral infections 
may trigger autoantibodies (1). The hypothesis stated that autoantibodies are primarily anti-
idiotype antibodies against virally-induced antibodies. This line of thought inferred that the 
viral protein and the corresponding host protein were ‘complementary antigens’ at a 
molecular level, giving rise to a pair of complementary immune responses – an antibody 
against a viral antigen and an antibody against a complementary host protein. 
‘Complementarity proteins’, as proposed in the late sixties, are defined as a pair of proteins 
encoded by the same gene - one from sense RNA and the second from antisense RNA - and 
translated in the same reading frame. As posited by the ‘molecular recognition’ theory, this 
pair of proteins possess a natural potential for physically joining due to inherent properties 
in shape, amino acid sequence, and hydropathy, which confers structurally complementary 
shapes likened to a key and a keyhole (2–4). These ideas have been supported by others, 
who propose that disease can be incited by an initial antibody response to an antigen that is 
‘complementary’ to the known autoantigen (5,6).
We previously reported that the sera of patients with anti-neutrophil cytoplasm antibody 
(ANCA) associated vasculitis contain antibodies reactive with ‘complementary’ proteinase 3 
(cPR3) (7,8). We proposed the theory of ‘autoantigen complementarity’, stating that 
immunopathogenesis of disease begins with formation of antibodies against a protein 
complementary to the autoantigen. This elicits a second antibody response against the 
idiotope of the primary antibody. The anti-idiotype antibodies, besides binding the idiotope 
of the primary antibody, consequently react with the ’sense’ protein, PR3. Epitope analysis 
of anti-cPR3 antibodies from patients’ sera verified their specificity for cPR3 (9,10). 
Patients were identified who had a memory T cell population that responded to cPR3 
peptide (11). Bearing in mind that antigen must have been presented to T cells at some 
point, MHC DRB1*1501 proteins, linked with increased risk for PR3-ANCA disease, were 
shown to bind to cPR3 peptide in an antigen-presenting manner (12).
These observations suggest that exposure to proteins complementary to autoantigens, 
whether from viral infections or not, can be disease-inciting. This is the first report of 
experiments designed to address this question. The classic antibody-mediated autoimmune 
glomerulopathy, Goodpasture's or anti-glomerular basement membrane (GBM) disease 
(13,14), is ideal for these studies, since the disease-associated epitope has been mapped to 
guide construction of a defined complementary peptide (15,16) and, importantly, there is an 
established animal model (17,18). The disease is caused by autoantibodies to a component 
of the GBM in the non-collagenous domain (NC1) of the α3 chain of type IV collagen, 
α3(IV)NC1 (19–21).
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Experimental autoimmune glomerulonephritis (EAG), an animal model of Goodpasture’s 
disease, can be induced in susceptible strains of rats and mice by immunization with 
solubilized GBM (17,18,22) or with recombinant α3(IV)NC1 (23–25). EAG shares many 
features with the human disease, in that the renal and lung pathology are very similar (26), 
and the anti-GBM antibodies show the same specificity for the main target antigen, 
α3(IV)NC1 (24). Wistar Kyoto (WKY) rats have been shown to be genetically susceptible 
to crescentic glomerulonephritis (27–30), and when immunized with α3(IV)NC1 develop 
circulating and deposited anti-GBM antibodies, with focal necrotizing crescentic 
glomerulonephritis and lung haemorrhage. It has been reported that peptides containing the 
T cell epitope pCol(28–40) induce severe glomerulonephritis, suggesting that the 
autoantibody response to GBM antigens could be induced by a single nephritogenic T cell 
epitope, with subsequent intra-molecular epitope spreading (31–33). In addition, we have 
shown that a B and T cell epitope pCol(24–38) can induce EAG (34) and that nasal 
administration of pCol(24–38) can reduce severity of EAG induced by α3(IV)NC1 via 
mucosal tolerance (35).
Our results indicate that a peptide complementary in sequence to the sense immunodominant 
peptide in EAG, pCol(24–38), when administered to WKY rats, causes autoimmune 
glomerulonephritis. Also presented are data showing that patients with anti-GBM disease 
express antibodies reactive with complementary α3(IV)NC1 peptide, supportive of a role for 
‘autoantigen complementarity’ in at least some cases of the human disease.
RESULTS
Derivation of pCol(24–38) complementary peptides
Peptides complementary to pCol(24–38), an α3(IV)NC1-derived peptide which induces 
anti-GBM disease in WKY rats (34), were designed by theoretical 5’ to 3’ transcription of 
the non-coding DNA strand into antisense RNA, followed by translation in the α3(IV)NC1 
reading frame (2,3) (Fig. 1a). The transcribed antisense RNA sequence includes a ‘stop’ 
codon complementary to a serine-encoding thymidine-cytosine-adenosine codon; however, 
substitution of the adenosine base with thymidine, cytosine, or guanidine replaces the 
antisense ‘stop’ with glycine (G) or arginine (R)-encoding codons without altering the sense 
pCol(24–38) amino acid sequence (Fig. 1b). Both these complementary peptides (c-α3-Gly 
and c-α3-Arg) were synthesized, as the side chains of these amino acids could potentially 
result in distinct peptide biochemical properties. A scrambled complementary peptide was 
also designed by random reordering of the c-α3-Gly sequence, which was confirmed by 
NCBI BLAST to have little homology to any described microbial or WKY rat sequences. 
Hydropathic scoring of c-α3-Gly and pCol(24–38) amino acid residues were opposite each 
another (Fig. 1c), as predicted for complementary protein pairs (4,36). Immunization of 
WKY rats with either of these pCol(24–38)-complementary peptide antigens would be 
predicted by the theory of autoantigen complementarity to result in anti-c-α3 idiotypic 
antibodies, followed by production of anti-idiotypic antibodies which are capable of binding 
to native rat kidney pCol(24–38) autoantigen, and should result in anti-GBM 
glomerulonephritis (Fig. 1d).
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Glomerulonephritis in WKY rats immunized with different antigens
The protocol used for pCol(24–38), c-α3-Gly, and c-α3-Arg immunization of WKY rats in 
our experiments at Imperial College London reliably induces anti-GBM disease by week 6 
when using α3(IV)NC1 or pCol(24–38) immunogens. As expected, pCol(24–38)-
immunized rats had marked albuminuria (Fig. 2a) and exhibited signs of systemic illness 
approximately 6 weeks post initial immunization. Rats immunized with either 
complementary peptide (c-α3-Gly or c-α3-Arg) had mild proteinuria and hematuria 
(Multistix dipstick; data not shown) at 6 weeks, but were otherwise healthy. However, we 
reasoned that anti-idiotypic antibody production and glomerulonephritis could be temporally 
delayed following complementary peptide immunization, and therefore elected to postpone 
euthanasia. By 8 weeks post immunization, moderate albuminuria had developed in 50% of 
c-α3-Gly immunized rats, so euthanasia of remaining animals was performed. Terminal 
urine collections from rats in both complementary peptide-immunized groups confirmed 
increased urine albumin concentration that was more severe in c-α3-Gly rats (Fig. 2b). 
Histopathologic examination of pCol(24–38) and c-α3-Gly-immunized rat kidneys revealed 
focal proliferative glomerulonephritis with segmental necrosis and/or crescent formation, 
although fewer glomeruli were affected and lesions were less severe in the c-α3-Gly group 
(Fig. 2b, c, d). In contrast, glomerular architecture was unremarkable in c-α3-Arg peptide-
immunized rats (Fig. 2b, e). Fluorescent GBM deposits of IgG on the GBM were evident in 
rats immunized with pCol(24–38) (strong, linear deposits, Fig. 2f) or c-α3-Gly (weak, 
intermittent deposits, Fig. 2g), but not c-α3-Arg (Fig. 2h). Reduction of disease secondary to 
substitution of a different single amino acid suggests that complementary sequences capable 
of initiating a pathologic immune response are highly restricted.
Two additional sets of immunizations were performed – one at the University of North 
Carolina (assisted by Dr. John Reynolds from Imperial College London), and a third at 
Imperial College London, using identical reagents. Included as an immunogen in these 
experiments, we used a scrambled peptide that contained the amino acid composition of c-
α3-Gly to confirm that disease induction in WKY rats was sequence driven rather than 
being a non-specific response to some other peptide characteristic. Albuminuria was evident 
in 24-h urine collections from sense pCol(24–38)-immunized rats (n=20) by week 4 
following immunization, increasing in severity by week 6 (Fig. 3a). Albuminuria also 
developed in c-α3-Gly-immunized rats (n=20) by week 4 and increased in severity at both 
week 6 and week 8, but magnitude was less than that seen in pCol(24–38)-immunized rats at 
every time point (Fig. 3a). In contrast, rats immunized with scrambled c-α3-Gly peptide 
(n=20) did not develop albuminuria at any time point (Fig. 3a). Histopathologic examination 
of kidneys confirmed development of glomerulonephritis in pCol(24–38) and c-α3-Gly-
immunized rats. By week 6, focal proliferative glomerulonephritis was evident in up to 85% 
of glomeruli in pCol(24–38)-immunized rats, with segmental necrosis and crescent 
formation in up to 45% of glomeruli, and strong linear deposits of IgG on the GBM evident 
by fluorescence microscopy (Fig. 3b, c). By week 8, focal proliferative glomerulonephritis 
became evident in up to 75% of glomeruli in c-α3-Gly-immunized rats, with segmental 
necrosis and crescent formation in up to 20% of glomeruli, and weak, intermittent GBM 
deposits of IgG (Fig. 3b, c). In contrast, rats immunized with the scrambled c-α3-Gly 
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peptide had persistently normal glomerular architecture at week 8, without any evident 
GBM deposits of IgG (Fig. 3b, c).
Characterization of the WKY rat immune responses
As shown previously (34), anti-α3(IV)NC1 antibodies were detected in sera from pCol(24–
38) immunized rats. Anti-α3(IV)NC1 antibodies (i.e. anti-idiotypic antibodies expected to 
develop after immunization with complementary peptide) were also detected in sera from c-
α3-Gly peptide-immunized rats, but not in sera from scrambled peptide-immunized animals 
(Fig. 4a). On Western blotting antibodies from pCol(24–38) immunized rats bound to 
monomer and dimer fractions of recombinant α3(IV)NC1. Antibodies from c-α3-Gly 
peptide-immunized rats bound primarily to monomer fractions of recombinant α3(IV)NC1, 
while animals immunized with the scrambled peptide showed no significant binding (Fig. 
4b). SDS-PAGE of collagenase-solubilized rat GBM showed a range of hexamer, dimer and 
monomer bands (Fig. 4c). Western blotting of sera from pCol(24–38) and c-α3-Gly-
immunized rats against these GBM fragments resulted in a similar binding pattern, whereas 
sera from rats immunized with scrambled peptide or adjuvant alone failed to bind (Fig. 4d).
Identification of a specific epitope on recombinant α3 protein recognized by anti-idiotypic 
antibodies using mass spectrometry
MALDI-MS/MS analysis identified two dominant rat α3 epitopes (GFIFTR and 
ALEPYVSR) bound by total IgG collected from c-α3-Gly-immunized rat serum (Fig. 5a). 
Comparison with the published α3(IV)NC1 bovine crystal structure suggests that these 
epitopes are located on the protein surface, and overlap with the pCol(24–38) peptide-
containing region (Fig. 5b). These two epitope sequences were synthesized and used to 
immunopurify anti-idiotypic antibodies from total rat IgG from animals immunized with c-
α3-Gly (Fig. 5c). The specificity of the affinity purified anti-idiotypic antibodies was 
demonstrated further by reactivity against purified NC1 hexamers from rat and bovine GBM 
by Western blotting, and to the GBM of normal rat tissue sections in an intermittent pattern 
by immunohistochemistry (Reynolds et al, unpublished observation).
Detection and isolation of anti-c-α3 peptide-reactive antibodies in patient sera
We asked if anti-c-α3-reactive antibodies were detectable in patients with anti-GBM 
disease. Anti-c-α3-reactivity was detected in sera from 47% (7/15) of anti-GBM disease 
patients (Fig. 6a). To determine whether this reactivity was due to an antibody population 
distinct from disease-associated anti-α3(IV)NC1 antibodies, total IgG was first isolated from 
plasmapheresis fluid, followed by anti-α3(IV)NC1 antibody affinity purification using a 
bovine collagen column. Three elution fractions from each patient were immunoreactive 
against α3(IV)NC1 peptide (Fig. 6b). When total IgG, affinity-purified anti-α3(IV)NC1 
IgG, and anti-α3(IV)NC1-depleted IgG were tested against c-α3-Gly peptide, 
immunoreactivity was present in total IgG and was retained following anti-α3(IV)NC1 
antibody depletion, confirming that these were in fact two separate antibody populations 
(Fig. 6c).
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Anti-GBM disease patients have antibodies reactive to recombinant human-c-α3-His 
protein
A longer, recombinant, hexahistidine-tagged, human c-α3 (rH-c-α3-His) protein was 
produced in a human cell line to improve immunodetection by using a post-translationally 
modified complementary antigen with secondary and tertiary structure, compared with the 
simpler structure expected in synthetic complementary peptides. Western blot probed with 
an anti-His antibody showed the multimeric forms of the recombinant protein 
(Supplementary data in Figure 1a of Appendix). The multimers were similar in size to the 
multimers derived from solubilisation of native NC1, visible in Fig. 3. Anti-GBM patients’ 
total IgG was capable of binding and immunopurifying 40 and 60 kD rH-c-α3-His 
multimers (Supplementary data in Figure 1b of Appendix). Data were reproducible using 
two separate batches of recombinant protein, one purified using fluid chromatography, and 
the second using a batch-purification approach (Supplementary data in Figure 1c of 
Appendix). Reactivity was not the result of a generalized increased reactivity to all antigens, 
as anti-GBM patients’ total IgG failed to bind other antigens tested, including hexahistidine-
tagged recombinant human PR3.
DISCUSSION
These findings, spanning both rat and human autoimmune kidney disease, can be 
incorporated into a pathogenic pathway that pivots on aspects of molecular 
‘complementarity’. We report a new laboratory model supporting the proof-of-principle that 
induction of autoimmune disease can follow an initial immune response to a complementary 
protein, and we provide indirect evidence that molecular ‘complementarity’ could be 
responsible for some cases of naturally-occurring anti-GBM disease in humans.
We induced autoantigen-specific antibodies and renal disease in WKY rats by immunization 
with a peptide ‘complementary’ in amino acid sequence to a well-described nephritogenic 
sense peptide. Epitope mapping of these anti-idiotypic, autoantigen-specific antibodies 
identified putative α3(IV)NC1-specific binding sites which overlap with the known rat and 
human anti-GBM disease autoantibody epitopes (16,21,37,38). Failure to induce disease 
following immunization with a scrambled peptide, and demonstration of peptide-specific 
splenocyte proliferation in rats with autoimmune glomerulonephritis (data not shown), 
strongly suggest that disease induction is due to an antigen-specific immunologic response 
rather than a consequence of immune complex deposition. We also demonstrated that a 
subset of anti-GBM disease patients have anti-idiotypic antibodies specific for 
complementary α3(IV)NC1 peptides and recombinant complementary α3(IV)NC1 protein, 
both of which are distinct from the pathogenic anti-α3(IV)NC1 autoantibodies, and which 
demonstrate idiotypic anti-idiotypic properties.
Antibody deposition within the glomeruli of c-α3-Gly-immunized rats with 
glomerulonephritis was predominantly intermittent rather than linear, as would have been 
expected in classic anti-GBM disease. A possible reason for this finding is incorrect 
selection of glycine or arginine as substitute amino acid residues at the ‘stop’ codon encoded 
by the antisense RNA sequence. The ‘true’ anti-GBM disease-inciting complementary 
antigen could, if exogenous in origin, have any amino acid present at this site. Alternatively, 
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endogenously-derived complementary antigens could be translated from DNA with SNPs or 
point mutations introduced during replication that then lead to alternative amino acid 
residues. As demonstrated in studies of T cell epitope spreading, single amino acid changes 
in peptide immunogen length may have dramatic effects on induction of disease (33). 
Truncation of amino terminal amino acids of the immunogenic peptide aborts EAG 
induction and the presence of asparagine at position 19 of the peptide is critical to disease 
induction (32). Atypical binding would also be related to the association between 
susceptibility to anti-GBM disease and certain MHC-II alleles noted in both patients (39,40) 
and laboratory rodents (27,30). The WKY rat strain used in our experiments is of the 
WKY/CR, RT1-l MHC-II haplotype, which is more susceptible to EAG than other WKY 
haplotypes. Relatively poor presentation of complementary peptides by MHC II variants 
could result in altered or inefficient affinity maturation of the anti-idiotypic anti-α3(IV)NC1 
antibodies, that then fail to bind the GBM in a linear fashion.
Immune responses to peptides are highly variable, and sequence analysis cannot predict 
whether humoral or cell-mediated (TH1, TH2 or TH17) responses will predominate 
following immunization. The peripheral T-lymphocyte repertoire in patients with anti-GBM 
disease is skewed toward a TH1 phenotype, but whether this precedes, and therefore 
influences, the immune response to a complementary antigen is unknown (41). Freund’s 
adjuvant, used here because of our success with similar immunization protocols in other 
rodent models of autoantigen complementarity (8), promotes a CD4+ TH1-dominant 
response to co-administered immunogens (42). Conversely, WKY rats are inherently biased 
towards CD4+ TH2 responses following immunization (43,44). Although future 
investigations could substitute TH2-favoring adjuvants such as aluminum salts, or use TH1-
biased rodent strains, we suspect that it is the overall inflammatory milieu at the time of 
exposure to a complementary antigen, in a host with some unidentified variant in genotype, 
which determines the initial autoimmune response and how it matures over time. Perhaps 
the immune response to a single complementary antigen results in development of anti-
GBM disease in some patients, as opposed to no appreciable effect, or an alternative 
glomerular disease, in other patients. This could indirectly explain why the magnitude 
and/or affinity of anti-c-α-3-Gly antibody responses were variable in our anti-GBM disease 
patients’ sera.
When WKY rats are immunized with microbe-derived peptides similar in amino acid 
sequence to pCol(24–38) (but in all cases dissimilar to c-α3-Gly), subtle variations in 
peptide sequence alter clinical manifestations of disease, and in all cases prevent the 
induction of anti-GBM antibodies (45). Our data support the primary conclusion drawn by 
the authors of that study, in that there is clearly inherent complexity in initiation of the anti-
α3(IV)NC1 immunological response. Our successful induction of anti-α3(IV)NC1 
antibodies via complementary peptide immunization is therefore perhaps surprising.
The data presented here, demonstrating that autoantigen complementarity could be 
responsible, in theory, for development of anti-GBM disease beg a larger question. As 
evidence has now been offered to support this theory in two dissimilar glomerular diseases 
(i.e. ANCA vasculitis and anti-GBM disease), then it is not a big step to suggest that 
molecular complementarity might contribute to the pathogenesis of other, non-renal 
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autoimmune diseases. Evidence already exists for molecular complementarity in patients 
with Sjogren's syndrome and systemic lupus erythematosus (SLE) (46); anti-idiotypic 
antibodies can be detected in patients’ sera using peptides complementary to the autoantigen 
B-cell epitopes (47), and mice immunized with either the B cell epitope peptide or its 
complement develop antibodies against both immunogens (48).
For all autoimmune diseases, it has long been thought that development of autoantibodies 
will incite disease. What is now evident is that circulating autoantibodies can exist in 
ostensibly healthy individuals for months if not years prior to the onset of their autoimmune 
disease, including SLE (49,50), ANCA vasculitis (51) and anti-GBM disease (52,53). The 
question that arises is what triggers the crucial event that pushes individuals into disease 
when they have had years of health with circulating autoantibodies. One proposal is that 
incitement of disease requires provoking the immune system with a pair of molecularly 
complementary antigens, consequently giving rise to a pair of complementary immune 
responses - an antibody to a ‘self’ antigen and an antibody against the complementary 
protein counterpart (5,6).
In summary, autoantigen complementarity merits further consideration as we strive to 
explain what induces autoimmune glomerulonephritis, or provokes disease in an individual 
after years of health in spite of expressing disease-related autoantibodies. It is conceivable 
that the titer of these “naturally occurring” autoantibodies is below threshold level, and that 
exposure to a complementary antigen potentiates the levels of autoantibodies through 
idiotypy. Regardless of the precise mechanisms involved, we have clearly shown for the first 
time that immunization with a complementary peptide can induce autoimmune 
glomerulonephritis in a rodent model, and that anti-complementary peptide antibodies can 
be detected in some patients with anti-GBM disease. The novelty and therapeutic potential 
of this research make it important that further work is performed to ascertain whether 
complementary proteins are important in the pathogenesis of autoimmune disease in general.
METHODS
Experimental animals
Male WKY rats, aged 8–10 weeks and weighing 120–150 g, were purchased from Charles 
River (Margate, Kent, UK) and Harlan Inc. (Indianapolis, IN, USA). All animals were 
housed in standard conditions and had free access to normal laboratory diet and water. All 
experimental procedures were conducted in accordance with the UK Animals (Scientific 
Procedures) Act of 1986 and the USA Animal Welfare Act of 1966.
Production of recombinant rat α3(IV)NC1
Recombinant rat α3(IV)NC1 was produced from a stably transfected HEK293 cell line, as 
previously described (24,54). Purification of recombinant rat α3(IV)NC1 from the 
supernatant was carried out by affinity chromatography using an anti-FLAG M2 affinity 
column (Sigma-Aldrich Company Ltd, Poole, UK).
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Production of synthetic peptides
The antisense sequence of the α3(IV)NC1 cDNA was determined by translation of 
accession number NM_031364 in the National Center for Biotechnology Information 
nucleotide data sequence bank. All peptides were synthesized by the University of North 
Carolina Microprotein Sequencing and Peptide Synthesis Facility.
Experimental protocol
Experiment 1—WKY rats were administered a single i.m. injection of sense pCol(24–38) 
peptide (n=6), c-α3-Gly peptide (COOH-ESSVTLGCGIRGARF-NH2) (n=6), or c-α3-Arg 
peptide (COOH-ESSVTLGCGIRRARF-NH2) (n=6) at a dose of 500µg/rat, in an equal 
volume of Freund's complete adjuvant (FCA, Sigma-Aldrich Company Ltd), as previously 
described (34). Blood was collected by tail artery puncture under light anaesthesia 
(Isofluorane), and 24 h urine specimens were obtained by placing animals in metabolic 
cages. Animals immunized with the sense peptide were killed at week 6 and animals 
immunized with the c-α3-Gly or c-α3-Arg peptides were killed at week 8.
Experiments 2 and 3—WKY rats were administered a single i.m. injection of sense 
peptide (pCol 24–38) (n=16), c-α3-Gly peptide (n=20) or scrambled peptide (n=20) at a 
dose of 500 µg/rat, in an equal volume of FCA (Sigma-Aldrich Company Ltd), or FCA 
alone (n=5) as a control. Animals immunized with the sense peptide were killed at week 6 
and animals immunized with the c-α3-Gly peptide or scrambled peptides were killed at 
week 8. Groups of WKY rats (n=5) were also immunized with recombinant rat α3(IV)NC1 
(Rec-α3) as a positive control or FCA alone as a negative control, as previously described 
(24).
Assessment of renal disease following peptide immunization
Albuminuria—Urinary albumin concentration was determined by rocket 
immunoelectrophoresis (Amersham Bioscience UK Limited), as previously described 
(18,26). Briefly, urine samples were subjected to immunoelectrophoresis at 60 v in an 
electrophoresis tank containing Barbitone buffer (BDH Laboratory Supplies), pH 9.5, for 6 
h, using a 1% agarose gel (BDH Laboratory Supplies) containing rabbit antisera to rat 
albumin. Albumin concentration was determined by comparison to rat serum albumin 
standards run in parallel and expressed in mg per 24 h.
Glomerular abnormalities—Kidney tissue was fixed in 10% neutral buffered formalin, 
processed and embedded in paraffin wax for light microscopy by standard techniques 
(Histopathology Department, South Kensington Campus, Imperial College London or 
Department of Pathology and Laboratory Medicine, UNC-Chapel Hill, NC). Briefly, 3 µm 
sections were stained with haemotoxylin and eosin (H&E), and periodic acid-Schiff (PAS). 
Fifty glomeruli per section were assessed and graded by a ‘blinded’ observer (HTC or JCJ) 
as: severe (extensive segmental necrosis/crescent formation), abnormal (segmental necrosis 
and/or extracapillary proliferation) or normal, and expressed as a percentage of glomeruli 
examined (18,26).
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Assessment of deposited antibodies after immunization with peptides
Deposition of IgG on the GBM: Deposits of IgG in the glomeruli were detected by direct 
immunofluorescence, as previously described (18,26). Tissue was embedded in OCT II 
embedding medium (Miles Inc, Elkhart, Indiana, USA) on cork discs, snap frozen in 
isopentane (BDH Laboratory Supplies, Poole, Dorset, UK) pre-cooled in liquid nitrogen, 
and stored at −70°C. Cryostat sections were cut 5 µm thick and incubated with fluorescein 
isothiocyanate (FITC) labelled rabbit anti-rat IgG (Serotec Ltd, Oxford, UK). Degree of 
immunostaining was graded from 0 to 3+ by a ‘blinded’ observer (HTC or JCJ).
Assessment of circulating antibody responses after immunization with peptides
Capture enzyme-linked immunosorbent assay (ELISA)—Anti-FLAG M2 
monoclonal antibody (Sigma-Aldridge Company Ltd) was coated onto ELISA plates (Life 
Technologies, Paisley, UK) at a concentration of 4 µg/ml in carbonate buffer pH 9.6 and 
incubated overnight. Plates were then incubated with Rec-α3 (2µg/ml) in carbonate buffer 
for 1 hour at 37°C. After blocking with 3% bovine serum albumin (BSA) for 1 h at 37°C, 
diluted sera (1:50) were applied for 1 h at 37°C. Bound antibody was detected by alkaline 
phosphatase conjugated goat anti-rat IgG (Sigma-Aldrich Company Ltd), using the substrate 
p-nitrophenyl phosphate (NPP, Sigma-Aldrich Company Ltd). Absorbency was read at 405 
nm using an Anthos Multiskan ELISA plate reader (Lab Tech International, Uckfield, UK), 
and results calculated as mean optical density for each triplicate sample (18,26).
SDS-PAGE and Western immunoblotting—Samples of purified NC1 domains of 
glomerular basement membrane (kindly provided by Dr Billy Hudson, Vanderbilt 
University Medical Center, Nashville, TN), and Rec-α3, were loaded onto a 12.5% SDS gel 
and electrophoresed at 50 v for 6 h (23,54). After transfer onto nitrocellulose paper, blots 
were incubated with sera from animals immunized with FCA alone (as a negative control), 
Rec-α3 (as a positive control), sense pCol(24–38), c-α3-Gly peptide or scrambled peptide at 
a dilution of 1:10. Bound antibody was detected by alkaline phosphatase conjugated sheep 
anti-rat IgG, (Sigma-Aldrich Company Ltd). Each blot was developed with 5-bromo-4-
chloro-3-indolyl phosphate/nitroblue tetrazolium (Sigma-Aldrich Company Ltd).
Assessment of anti-idiotypic-antibody epitope specificity
Total IgG from sera of c-α3-Gly-immunized WKY rats was analyzed for antibodies specific 
for Rec-α3 (55). Immobilized IgG was incubated with Rec-α3 and then subjected to 
proteolytic digestion. Resulting bound peptides were identified by MALDI-mass 
spectrometry and MS/MS. Total IgG from sera of scrambled-peptide immunized rats served 
as a control.
Anti-GBM patient sera and plasmapheresis samples
Because of the rarity of anti-GBM disease, samples were acquired from several sources. 
Twenty serum samples from 19 patients were obtained from the Glomerular Disease 
Collaborative Network (GDCN) biologic sample repository. Samples were identified using 
an initial search for a final diagnosis of anti-GBM disease (n=79), and then by eliminating 
those patients with morphologic diagnoses other than rapidly progressive or proliferative 
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glomerulonephritis (n=28), patients with anti-GBM titers less than 40.0 IU/L (n=3), and 
patients with anti-MPO or anti-PR3 ANCA titers greater than 16.0 IU/L (n=28). Additional 
serum samples were obtained from anti-GBM patients that were diagnosed or evaluated at 
the UNC-Chapel Hill School of Medicine during the time that the work described here was 
performed (n=6), or kindly provided by Dr. Thomas Hellmark, Lund University, Sweden 
(n=7), or Professor Charles Pusey, Hammersmith Hospital, Imperial College London (n=6). 
Epidemiologic data on these patients such as age, gender, or race was not collected, but anti-
GBM, anti-PR3, and anti-MPO antibody titers were recorded and reported when relevant. 
Plasmapheresis fluid was available from seven patients who were initially diagnosed and 
treated at UNC-Chapel Hill. All samples were maintained at −80°C from the time of 
collection until use. Samples were collected, stored, and accessed following review by the 
UNC Institutional Review Board (IRB), and informed patient consent was obtained.
Total IgG, α3(IV)NC1-specific, and complementary α3(IV)NC1-specific antibody purification
Total IgG purification and affinity purification of antibodies were performed by FPLC 
(AKTA FPLC with Frac-950 and Unicorn Software; GE Healthcare). Human 
plasmapheresis fluid was obtained from the UNC-Chapel Hill apheresis facility following 
approval by the IRB and informed patient consent. Total IgG was purified by precipitation 
of total serum proteins with 50% ammonium sulfate, resuspensded into approximately 20 
mL PBS, and dialyzed into PBS over 72 hrs with three successive dialysate switches.
Human anti-GBM disease assessment for the presence of anti-α3(IV)NC1 antibodies
Total IgG was isolated from plasmapheresis fluid from two patients with anti-GBM disease 
followed by purification on a bovine α3(IV)NC1 (generously provided by Dr. Thomas 
Hellmark) affinity column (HiTrap NHS-activated HP column, Amersham Biosciences) by 
FPLC (AKTA, GE Biosciences). Total IgG, affinity-purified anti-α3(IV)NC1 antibodies, 
and flow-through (anti-α3(IV)NC1 depleted IgG) were tested for reactivity against 
complementary protein by ELISA. EIA/RIA high-binding 96-well plates (Costar) were 
coated overnight at 4°C with antigen (0.25–5.0 ug/mL) and then blocked for 2 h in 1% BSA 
in PBS at room temperature. Patient sera were diluted 1:50–1:100 in 0.1% BSA in PBS and 
incubated for 2 h at room temperature. Alkaline phosphatase-conjugated secondary antibody 
was added for 1 h at room temperature. Optical density (OD) at 405nm was measured after 
substrate addition using a VERSAmax tunable microplate reader (Molecular Devices). 
Immunoreactivity was defined as an OD above the mean plus two standard deviations of the 
normal controls.
Recombinant human α3 protein production and purification
Conditioned medium containing recombinant complementary α3(IV)NC1 from transformed 
HEK293 cells was collected as follows. For each IP reaction 10 mL of media was incubated 
with 3 µg/mL of rabbit-origin anti-hexahistidine antibody, 3 µg/mL rabbit-origin negative 
control, 50 µg/mL anti-GBM patient IgG, or approximately 2 µg/mL of purified anti-
α3(IV)NC1 antibodies (negative control). Protein-antibody complexes were harvested with 
50% protein A/G slurry, subjected to SDS-PAGE, and transferred to nitrocellulose 
membranes as previously described. Nitrocellulose blots were probed with anti-
hexahistidine antibody (1:100 dilution) to detect presumptively isolated recombinant 
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complementary α3(IV)NC1. Duplicate immunoblots were also probed in parallel with a 
rabbit-origin anti-collagen IV antibody.
Statistical analysis
Differences between data were determined by the Mann Whitney U test. ANOVA was used 
to confirm differences between multiple data.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Complementary peptide derivation and study design
(A) Derivation of ‘complementary’ peptide to pCol(24–38). Amino acids known to be part 
of the anti-GBM epitope in human disease are indicated by open circles, and are aligned 
with the peptide that causes disease in rats. Identical amino acids are shown in alignment 
with connecting black lines. Complementary peptides are shown with the carboxy terminus 
to the left such that sense-antisense complementary amino acids are in line with each other. 
Peptides with amino acid residues denoted with an asterisk (*) were synthesized with either 
a glycine or arginine at this residue site. (B) Mutation of the third nucleotide in the indicated 
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codon preserves the serine residue in the sense strand, but changes the antisense amino acid 
to either a glycine (G) or arginine (R) residue to produce peptides 1 or 2. (C) By employing 
the hydropathic scoring system of Kyte and Doolittle, an opposite pattern of hydropathic 
scores was observed, as is characteristic of amino acids between the complementary peptide 
pairs. (D) Schematic of working hypothesis: WKY rats immunized with c-α3-Gly peptide 
will produce primary antibodies against the immunogen. Secondarily produced anti-
idiotypic antibodies will recognize α3(IV)NC1 protein in the kidney, due to 
‘complementarity’, and cause disease.
Reynolds et al. Page 17














Assessment of renal disease in groups of WKY rats (n=6) immunized with sense pCol(24–
38) peptide, and anti-sense peptides c-α3-Gly and c-α3-Arg. Results shown represent 
individual animals in each group at week six after immunization for pCol(24–38) and week 
eight after immunization for c-α3-Gly and c-α3-Arg. (A) Urine analysis for albumin 
excretion (*p<0.001; pCol(24–38) versus c-α3-Arg, **p<0.05; c-α3-Gly versus c-α3-Arg). 
(B) Glomerular abnormalities graded as severe (extensive segmental necrosis/crescent 
formation), abnormal (segmental necrosis and/or extracapillary proliferation), or normal 
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(*p<0.001; pCol(24–38) versus c-α3-Arg, **p<0.01; c-α3-Gly versus c- α3-Arg). (C–E) 
Light microscopy of kidney tissue showing: (C) marked segmental fibrinoid necrosis of the 
glomerular tuft with crescent formation at week 6 from an animal immunized with pCol(24–
38); (D) severe crescentic glomerulonephritis with fibrinoid necrosis at week 8 from an 
animal immunized with c-α-3-Gly; and (E) normal glomerular architecture from an animal 
immunized with c-α3-Arg. (F–H) Direct immunofluorescence of kidney tissue showing: (F) 
strong linear deposits of IgG along the GBM at week 6 from an animal immunized with 
pCol(24–38), (G) weak, intermittent deposits of IgG at week 8 from an animal immunized 
with c-α3-GLY and (H) background fluorescence from an animal immunized with c-α3-
Arg. Magnification ×300.
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Assessment of renal disease in combined groups of WKY rats (n=20) immunized with 
pCol(24–38) peptide, c- 3-Gly peptide and scrambled peptide. Results shown represent the 
mean ± SD in each group. (A) albuminuria at different time points after immunization 
(*p<0.001; pCol(24–38) versus scrambled, and c- 3-Gly versus scrambled), (B) glomerular 
abnormalities at week 6 or week 8 after immunization (*p<0.005; pCol(24–38) versus 
scrambled, **p<0.05; c- 3-Gly versus scrambled), and (C) deposits of IgG on the GBM at 
week 6 or week 8 after immunization (*p<0.001; pCol(24–38) versus scrambled).
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WKY rats immunized with c-α3-Gly peptide developed antibodies directed towards 
α3(IV)NC1. (A) Sera from animals immunized with c-α3-Gly peptide contained circulating 
antibodies reactive with recombinant α3(IV)NC1 by capture ELISA (*p<0.001; c-α3-Gly 
versus scrambled). (B) Sera from animals immunized with pCol(24–38) and c-α3-Gly 
peptide were reactive with recombinant α3(IV)NC1 by Western blotting. (C) Coomassie 
stained gel of collagenase-solubilised rat glomerular basement membrane (GBM) NC1 
collagen IV (kindly provided by Dr. Billy Hudson) showed a range of hexamer, dimer and 
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monomer bands. (E) Sera from animals immunized with c-α3-Gly peptide bound to NC1 
hexamers and α3 monomers from GBM, similar to that from the sense pCol(24–38) peptide 
immunized animals. Positive control sera from animals immunized with recombinant rat 
α3(IV)NC1, and negative control sera from pre-immune animals and from animals given 
adjuvant alone.
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Anti-idiotypic antibodies isolated from c-α3-Gly immunized animals were reactive to 
recombinant α3(IV)NC1. (A) Anti-idiotypic antibody epitope analysis by MS/MS identified 
two predominant epitopes on recombinant α3(IV)NC1 (GFIFTR and ALEPYVSR). (B) 
Epitopes of anti-idiotypic antibodies and their proximity to the amino acid sequence of the 
sense pCol(24–38) peptide (green), anti-sense c-α3-Gly peptide (blue) and amino acid 
overlap (red) (C) Affinity purified IgG from animals immunized with c-α3-Gly peptide 
showed enriched reactivity against recombinant α3(IV)NC1 compared to total IgG.
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Anti-c-α3-Gly antibodies are detectable in a subset of sera from patients with anti-GBM 
disease. (A) Sera reactivity against human c-α3-Gly peptide by ELISA (*p<0.008; patients 
versus healthy controls). (B) Affinity purified IgG from bovine type IV collagen was 
reactive with α3(IV)NC1. (C) Anti-c-α3-Gly and anti-α3(IV)NC1 immunoreactivity are due 
to two separate antibody populations. Total IgG, affinity-purified anti-α3(IV)NC1 
antibodies, and anti-α3(IV)NC1 depleted IgG were tested for reactivity against c-α3-Gly 
peptide. Affinity purified anti-α3(IV)NC1 antibodies reacted with α3(IV)NC1, but not c-α3-
Gly peptide. In comparison, the c-α3-Gly reactivity remained in the IgG pool depleted of 
anti-α3(IV)NC1 antibodies.
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